Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Advanced HER2+Breast Cancer × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2157 Neoplasms 1655 Carcinoma, Non-Small-Cell Lung 1431 Prostatic Neoplasms 1205 Colorectal Neoplasms 984 Lung Neoplasms 875 Neoplasm Metastasis 742 Multiple Myeloma 723 Leukemia, Myeloid, Acute 701 Ovarian Neoplasms 611 Pancreatic Neoplasms 607 Melanoma 602 Squamous Cell Carcinoma of Head and Neck 525 Recurrence 516 Carcinoma, Hepatocellular 501 Brain Neoplasms 480 Glioblastoma 457 Stomach Neoplasms 452 Head and Neck Neoplasms 427 Lymphoma 417 Triple Negative Breast Neoplasms 414 Uterine Cervical Neoplasms 397 Precursor Cell Lymphoblastic Leukemia-Lymphoma 390 Carcinoma, Renal Cell 373 Lymphoma, Non-Hodgkin 359 Endometrial Neoplasms 349 Sarcoma 327 Urinary Bladder Neoplasms 324 Lymphoma, Large B-Cell, Diffuse 313 Glioma 313

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04208178 2026-02-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡